The USA- based Presidential Emergency Plan for AIDS Relief is the object of several calls for change from other HIV/AIDS campaigns. In its fourth year, the PEPFAR claims to provide antiretroviral drugs to 822,000 people worldwide, although the campaign's target for five years is coverage for two million patients.
The Institute of Medicine recommended that the PEPFAR should adopt the World Health Organization's protocol for the approval of drugs to be distributed in the program, introducing better data tracking and collection, in order to target the people who are most at risk of HIV/AIDS. In an implicit criticism of President George W Bush's initiative, the IOM calls for "maintaining and/or increasing effective HIV prevention programs:" the President's program insists that a proportion of the grants are awarded to "abstinence-promoting" organizations, although the PEPFAR is not bound by US federal rules prohibiting donations to aid organizations that promote or perform abortions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze